Novartis to acquire Chinook Therapeutics for US$ 3.2 bn
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Subscribe To Our Newsletter & Stay Updated